Related Experiment Video
Updated: Jun 26, 2026

Murine Model of Central Venous Stenosis using Aortocaval Fistula with an Outflow Stenosis
Published on: July 11, 2019
Management of cephalic arch stenosis in hemodialysis access: Updated systematic review and meta-analysis
Hyangkyoung Kim1, Young Shin Kim2, Nicos Labropoulos3
1Department of Surgery, College of Medicine, Ewha Womans University, Seoul, Korea.
Insights
Cephalic arch stenosis (CAS) treatment outcomes were assessed. Surgical transposition (STG) showed superior primary patency compared to other methods, suggesting it as a potential primary treatment option.
Area of Science:
- Vascular Surgery
- Interventional Nephrology
- Medical Technology Assessment
Background:
- Cephalic arch stenosis (CAS) is a recurrent complication in hemodialysis access, often resistant to treatment.
- Current treatment outcomes for CAS are not well-validated, necessitating further clinical assessment.
Purpose of the Study:
- To evaluate the clinical outcomes of various treatments for cephalic arch stenosis (CAS) in patients undergoing hemodialysis access.
- To compare the efficacy of different treatment modalities for CAS through meta-analysis.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials (RCTs) and non-RCTs were conducted, searching electronic databases up to December 4, 2023.
- Network meta-analyses (NMA) were employed to compare odds ratios (OR) and cumulative ranking curves across different treatment modalities.
- The review adhered to PRISMA-P guidelines and is registered in PROSPERO (CRD42022296513).
Main Results:
- The analysis included 4 RCTs and 15 non-RCTs, with significant heterogeneity observed in fistula type and patient conditions.
- No significant difference in primary patency was found between drug-coated balloons (DCB) and percutaneous transluminal angioplasty (PTA) at 6 and 12 months (low certainty evidence).
- Surgical transposition (STG) demonstrated favorable results compared to stents or PTA at 3, 6, and 12 months, with primary patency rankings at 12 months: STG (92.7%), transposition (76.0%), stent (67.5%), PTA (64.5%), and DCB (46.3%).
Conclusions:
- Despite data limitations and low-certainty evidence, STG may be a preferred primary treatment for CAS when applicable.
- STG shows potential for superior primary patency and higher treatment ranking compared to other interventions for CAS.
- Further research is needed to solidify evidence on CAS treatment efficacy.
Introduction:
Cephalic arch stenosis (CAS) is often recurrent, resistant to treatment and the intervention outcome is not well validated so far. We purposed to assess the clinical outcomes of CAS treatment in patients with hemodialysis access.
Methods:
Electronic bibliographic sources were searched up to December 4 2023 to identify studies reported outcome after treating CAS. Direct and indirect evidence was combined to compare odds ratios (OR) and surfaces under the cumulative ranking curves across the different treatment modalities through meta-analysis and network meta-analyses (NMA). This systematic review was conducted in accordance with the PRISMA-P. The review is registered in PROSPERO (CRD42022296513).
Results:
Four randomized controlled trials (RCTs) and 15 non-RCTs were included in the analysis. The study population differed in fistula type, restenosis or thrombosis, and significant heterogeneity was observed among the publications. The risk of bias was low to serious. Meta-analysis found no significant difference between DCB and PTA in primary patency at 6 and 12 months (OR 1.16 and 0.60, respectively; low certainty of evidence). Favorable result with STG compared to stent or PTA at 3, 6, and 12 month was observed (OR 4.28, 5.13, and 13.12, and 4.28, 5.13, 13.12, respectively; low certainty of evidence). Regarding primary patency, the treatment rankings, from highest to lowest, were STG (92.7%), transposition (76.0%), stent (67.5%), DCB (46.3%), and PTA (64.5%) at 12 months.
Conclusion:
Despite data limitations, the low-quality evidence suggests that STG may merit consideration as a primary treatment option when all alternatives are applicable, given their potential for better primary patency and higher treatment ranking.
Related Concept Videos
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease III: Interprofessional Care

